Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback